Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C13H13N3O6S |
| Molecular Weight | 339.324 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(=O)OCC1=C(N2[C@H](SC1)[C@H](NC(=O)CC#N)C2=O)C(O)=O
InChI
InChIKey=RRYMAQUWDLIUPV-BXKDBHETSA-N
InChI=1S/C13H13N3O6S/c1-6(17)22-4-7-5-23-12-9(15-8(18)2-3-14)11(19)16(12)10(7)13(20)21/h9,12H,2,4-5H2,1H3,(H,15,18)(H,20,21)/t9-,12-/m1/s1
| Molecular Formula | C13H13N3O6S |
| Molecular Weight | 339.324 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Cephacetrile, a parenteral cephalosporin, is a broad-spectrum first generation cephalosporin antibiotic effective in Gram-positive and Gram-negative bacterial infections. It works by inhibition of bacterial cell wall synthesis. It attains high serum levels and is excreted quickly via the urine. By binding to specific penicillin-binding proteins (PBPs) located inside the bacterial cell wall, it inhibits the third and last stage of bacterial cell wall synthesis. Cephacetrile was used in the treatment of female pelvic inflammatory disease, meningitis and number of other systemic, respiratory and urinary infections.
Approval Year
Cmax
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
122.2 μg/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4479808/ |
15 mg/kg single, intravenous dose: 15 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
CEPHACETRILE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
AUC
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
71 μg × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4479808/ |
15 mg/kg single, intravenous dose: 15 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
CEPHACETRILE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
T1/2
| Value | Dose | Co-administered | Analyte | Population |
|---|---|---|---|---|
2 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/4479808/ |
15 mg/kg single, intravenous dose: 15 mg/kg route of administration: Intravenous experiment type: SINGLE co-administered: |
CEPHACETRILE plasma | Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
PubMed
| Title | Date | PubMed |
|---|---|---|
| [Antimicrobial sensitivity of coagulase-positive staphylococcal strains isolated from bovine mastitis in the central dairy catchment area of Argentina ]. | 2002-11-06 |
|
| Relationship among plasmids recovered from Staphylococcus aureus, milk leukocytes, and antimicrobial resistance. | 2001-12 |
Patents
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/950258
This pharmacokinetic investigation was based on the determination of serum and urinary levles of cephacetrile in 50 subjects given single intramuscular or intravenous doses of 0.5 or 1 gm of the antibiotic; 30 normal subjects, 10 patients with renal insufficiency, and 10 patients with chronic nephritis undergoing maintenance haemodialysis were included in this study.
Route of Administration:
Parenteral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/4377
The MICs were 0.06 to 0.5 ug/ml for Group A Streptococcus, D. pneumoniae, and Staph. aureus, 4-6 ug/ml for E. coli and Klebsiella-Enterobacter 8-32 ug/ml for Pr. mirabilis and more than 500 ug/ml for Ps. aeruginosa. A few strains of Klebsiella and E. coli had MICs of more than 125 ug/ml.
| Substance Class |
Chemical
Created
by
admin
on
Edited
Mon Mar 31 18:24:32 GMT 2025
by
admin
on
Mon Mar 31 18:24:32 GMT 2025
|
| Record UNII |
FDM21QQ344
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Preferred Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English |
| Classification Tree | Code System | Code | ||
|---|---|---|---|---|
|
WHO-VATC |
QJ51RD34
Created by
admin on Mon Mar 31 18:24:32 GMT 2025 , Edited by admin on Mon Mar 31 18:24:32 GMT 2025
|
||
|
NCI_THESAURUS |
C357
Created by
admin on Mon Mar 31 18:24:32 GMT 2025 , Edited by admin on Mon Mar 31 18:24:32 GMT 2025
|
||
|
WHO-VATC |
QJ51DB10
Created by
admin on Mon Mar 31 18:24:32 GMT 2025 , Edited by admin on Mon Mar 31 18:24:32 GMT 2025
|
||
|
WHO-VATC |
QJ01DB10
Created by
admin on Mon Mar 31 18:24:32 GMT 2025 , Edited by admin on Mon Mar 31 18:24:32 GMT 2025
|
||
|
WHO-ATC |
J01DB10
Created by
admin on Mon Mar 31 18:24:32 GMT 2025 , Edited by admin on Mon Mar 31 18:24:32 GMT 2025
|
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
91562
Created by
admin on Mon Mar 31 18:24:32 GMT 2025 , Edited by admin on Mon Mar 31 18:24:32 GMT 2025
|
PRIMARY | |||
|
524
Created by
admin on Mon Mar 31 18:24:32 GMT 2025 , Edited by admin on Mon Mar 31 18:24:32 GMT 2025
|
PRIMARY | |||
|
3007
Created by
admin on Mon Mar 31 18:24:32 GMT 2025 , Edited by admin on Mon Mar 31 18:24:32 GMT 2025
|
PRIMARY | |||
|
DTXSID0022779
Created by
admin on Mon Mar 31 18:24:32 GMT 2025 , Edited by admin on Mon Mar 31 18:24:32 GMT 2025
|
PRIMARY | |||
|
SUB06162MIG
Created by
admin on Mon Mar 31 18:24:32 GMT 2025 , Edited by admin on Mon Mar 31 18:24:32 GMT 2025
|
PRIMARY | |||
|
10206-21-0
Created by
admin on Mon Mar 31 18:24:32 GMT 2025 , Edited by admin on Mon Mar 31 18:24:32 GMT 2025
|
PRIMARY | |||
|
233-508-8
Created by
admin on Mon Mar 31 18:24:32 GMT 2025 , Edited by admin on Mon Mar 31 18:24:32 GMT 2025
|
PRIMARY | |||
|
C81037
Created by
admin on Mon Mar 31 18:24:32 GMT 2025 , Edited by admin on Mon Mar 31 18:24:32 GMT 2025
|
PRIMARY | |||
|
100000081375
Created by
admin on Mon Mar 31 18:24:32 GMT 2025 , Edited by admin on Mon Mar 31 18:24:32 GMT 2025
|
PRIMARY | |||
|
m1063
Created by
admin on Mon Mar 31 18:24:32 GMT 2025 , Edited by admin on Mon Mar 31 18:24:32 GMT 2025
|
PRIMARY | Merck Index | ||
|
FDM21QQ344
Created by
admin on Mon Mar 31 18:24:32 GMT 2025 , Edited by admin on Mon Mar 31 18:24:32 GMT 2025
|
PRIMARY | |||
|
CHEMBL2110602
Created by
admin on Mon Mar 31 18:24:32 GMT 2025 , Edited by admin on Mon Mar 31 18:24:32 GMT 2025
|
PRIMARY | |||
|
DB01414
Created by
admin on Mon Mar 31 18:24:32 GMT 2025 , Edited by admin on Mon Mar 31 18:24:32 GMT 2025
|
PRIMARY | |||
|
CEFACETRILE
Created by
admin on Mon Mar 31 18:24:32 GMT 2025 , Edited by admin on Mon Mar 31 18:24:32 GMT 2025
|
PRIMARY | |||
|
D002505
Created by
admin on Mon Mar 31 18:24:32 GMT 2025 , Edited by admin on Mon Mar 31 18:24:32 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
SALT/SOLVATE -> PARENT |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
|
ACTIVE MOIETY |
|